SCHEMBL6607925

SCHEMBL6607925

C=C(C(=O)OC)N(Cc1ccccc1NC(=O)CCc1ccccc1)S(=O)(=O)c1ccc(OC)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.50
GRK2 P25098 1/20 0.50
PPARG P37231 1/20 0.50
KMT2A Q03164 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.50
NR2E3 Q9Y5X4 1/20 0.50
NCOR2 Q9Y618 1/20 0.50
GAA P10253 1/20 0.48
BMP1 P13497 3/20 0.47
TP53 P04637 2/20 0.46
MMP3 P08254 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TAS2R14 Q9NYV8 2/20 0.45
PTGES O14684 1/20 0.45
TAS2R8 Q9NYW2 1/20 0.45
CXCR3 P49682 1/20 0.45
KDM4E B2RXH2 3/20 0.44
HDAC1 Q13547 1/20 0.44
KEAP1 Q14145 1/20 0.44
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6610937 0.87 POLB (0.48) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6608669 0.87 KMT2A (0.48) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6614500 0.86 KMT2A (0.52) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL5656058 0.86 POLB (0.48) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL5656436 0.85 LMNA (0.48) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6609835 0.84 POLB (0.48) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6610841 0.84 KEAP1 (0.48) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6608096 0.83 ALDH1A1 (0.50) KMT2AGAAALDH1A1TAS2R14CXCR3
SCHEMBL6611811 0.82 KDM4E (0.48) POLBGRK2PPARGKMT2ACTDSP1
SCHEMBL6609938 0.82 MAPT (0.48) POLBKMT2ACTDSP1NCOR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147095-B1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS WYETH CORP (US) 2004-08-11 EP disclosed
US-6544984-B1 Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. AMERICAN CYANAMID COMPANY 2003-04-08 US disclosed
EP-1147095-A1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2001-10-24 EP disclosed
EP-1051407-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2000-11-15 EP disclosed
WO-2000044730-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-08-03 WO disclosed
US-6071903-A ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-06-06 US disclosed
WO-1999037625-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1999-07-29 WO disclosed